Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allurion Technologies, Inc. (NYSE: ALUR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Allurion’s medical device business focused on metabolically healthy weight loss, its Allurion Program, and the Allurion Smart Capsule, which the company describes as a swallowable, Procedureless™ gastric balloon for weight loss and an investigational device in the United States.
Through periodic reports and current reports on Form 8-K, Allurion outlines financial results, capital structure changes, and governance matters. Filings referenced in recent disclosures include notifications of late filing on Form 12b-25, restatements related to accounting for a revenue interest financing agreement and convertible senior secured notes, and descriptions of material weaknesses in internal control over financial reporting. Investors can review these filings to understand how non-cash accounting adjustments affect items such as Other Comprehensive Income (Loss) and Other Income (Expense), as well as the company’s commentary that these corrections are not expected to impact revenue, gross margin, operating expenses, or cash.
Allurion’s SEC filings also describe capital markets and financing transactions, such as a private placement of common stock and accompanying warrants, and an exchange agreement to convert outstanding debt and obligations under revenue interest financing agreements into shares of Series B convertible preferred stock, subject to stockholder approval and exchange listing requirements. Definitive proxy materials provide further detail on proposals for stockholders, including amendments to stock plans, option repricing, preferred share and warrant share issuances, and a potential reverse stock split within an approved ratio range.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the key points of complex documents like 10-Ks, 10-Qs, 8-Ks, and proxy statements in plain language. Users can quickly see the main themes in Allurion’s disclosures on regulatory progress for the Allurion Smart Capsule, financial performance, risk factors, and governance decisions, while still having access to the full original SEC documents for deeper analysis.
Allurion Technologies, Inc. reported the results of its 2025 annual stockholder meeting held on December 18, 2025. Stockholders re-elected three directors — Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey — to serve until the 2028 annual meeting. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Stockholders approved an amended and restated 2023 Stock Option and Incentive Plan that increases the shares authorized for issuance, updates the definition of Fully-Diluted Shares Outstanding, lowers the non-employee director compensation limit, and extends the plan term. They approved repricing certain outstanding stock options under that plan, and authorized issuing common shares upon conversion of Series B Preferred Stock and upon exercise of certain private placement warrants to comply with NYSE listing rules.
Stockholders also approved an amendment to the certificate of incorporation to allow a reverse stock split at a ratio between 1-for-1.5 and 1-for-20, with the exact ratio to be set by the Board. A contingent proposal to adjourn the meeting was not needed because all key proposals received sufficient support.
Allurion Technologies, Inc. director insider transactions show a mix of gifts and small open-market sales of common stock following a reverse stock split. The filing notes that on January 3, 2025, Allurion implemented a 1-for-25 reverse stock split, and all share amounts in this report are adjusted for that change. On October 3, 2025 and November 26, 2025, the director reported code "G" transactions, reflecting transfers of common stock between direct holdings and an indirect position held through the Davin Family Nominee Trust, at a reported price of $0.00 per share.
On December 3, 2025 and December 4, 2025, the trust reported code "S" sales of 1,606 common shares on each date, at prices of $1.48 and $1.5821 per share, respectively, reducing the indirect holdings reported for the trust to zero. The filing explains that the shares attributed to the trust are held by the Davin Family Nominee Trust, for which the reporting person and spouse serve as trustees, and that the reporting person disclaims beneficial ownership beyond any pecuniary interest.
ALUR has a shareholder planning to sell 3,212 shares of common stock under Rule 144. The proposed sale will be executed through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/02/2025 and an aggregate market value of
The shares to be sold were acquired in two transactions. One block of 2,608 shares was obtained on
Allurion Technologies, Inc. (ALUR) is asking stockholders to vote at its fully virtual 2025 annual meeting on December 18, 2025. Stockholders of record as of October 31, 2025, when 7,770,047 common shares were outstanding, may participate and vote.
Key items include electing three Class II directors to serve until 2028 and ratifying Deloitte & Touche LLP as independent auditor for 2025, after audit fees of $1,483,750 in 2024 and $2,617,825 in 2023. The Board also requests approval of an amended and restated 2023 equity incentive plan, which would significantly increase the share pool to up to 20% of fully diluted shares following a planned exchange transaction and add an automatic annual increase of up to 5% of fully diluted shares through 2035.
The proxy further seeks approval of a one-time option repricing for up to 110,990 deeply underwater options, resetting exercise prices to at least the market price on the approval date, subject to a one-year retention condition. Additional proposals cover preferred share issuance, private placement warrant share issuance, a potential reverse stock split, and the ability to adjourn the meeting if needed.
Allurion Technologies (ALUR) reports sharply weaker results for the quarter ended September 30, 2025. Revenue fell to $2.7 million from $5.4 million a year earlier, while the company swung from net income of $8.7 million to a net loss of $11.9 million, driven by lower sales and continued operating expenses. For the first nine months of 2025, revenue declined to $11.6 million from $26.5 million, with a net loss of $22.7 million versus net income of $2.4 million in the prior-year period.
Allurion ended the quarter with $6.1 million in cash and cash equivalents and total assets of $18.1 million, against total liabilities of $101.1 million, including a $49.9 million Revenue Interest Financing liability and $32.2 million of convertible notes payable. Stockholders’ deficit widened to $82.9 million, even after increasing common shares outstanding to 7,767,027 from 2,710,607 at December 31, 2024.
Allurion Technologies, Inc. filed a notice of late filing for its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, explaining that it needed extra time to prepare and review items that occurred after quarter end. That work is now complete, and the company expects to file the Form 10-Q on the date of this notice, within the five-day extension allowed.
Allurion expects to report total revenue of approximately $2.7 million for the three months ended September 30, 2025, compared with approximately $5.4 million a year earlier. Gross profit is expected to be about $1.3 million versus $3.1 million, with lower operating expenses: sales and marketing of about $3.1 million, research and development of about $2.0 million, and general and administrative of about $5.8 million. Loss from operations is expected to be approximately $9.6 million, improved from approximately $12.3 million in the prior-year quarter.
Allurion Technologies, Inc. (ALUR)RTW Investments, LP acquired common stock and accompanying warrants in a private placement. The reporting entities bought blocks of 991,544, 767,848 and 96,896 shares of common stock, each with matching warrants, at a purchase price of $1.67 per share and accompanying warrant. Following these transactions, the funds report beneficial ownership of up to 3,138,798, 2,427,089 and 298,992 shares through different RTW-managed vehicles, plus an additional 26,551 shares in another fund. The warrants carry an exercise price of $1.67 per share, become exercisable only after stockholder approval, and expire five years after that approval. Each warrant is subject to a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election), and Allurion has agreed to use its reasonable best efforts to hold a stockholder meeting no later than January 31, 2026 to seek approval for the warrant share issuance.
Allurion Technologies (ALUR): RTW Investments and affiliates filed an amended Schedule 13D disclosing 48.1% beneficial ownership, or 5,891,430 shares, based on 12,249,232 shares outstanding upon the private placement closing.
On November 11, 2025, RTW agreed to exchange remaining note principal, $48.0 million under a 2023 revenue interest financing agreement and $9.5 million under a 2024 agreement for Series B convertible preferred stock. The preferred has an 8.25% dividend, is convertible at $3.37 per share of common stock, and includes a 9.9% beneficial ownership conversion cap. Closing is subject to stockholder approval and listing/effectiveness conditions.
RTW funds also bought 1,856,288 shares with accompanying warrants at $1.67 per unit for approximately $3.1 million. Governance terms allow RTW to nominate one or two directors while it holds at least 10% or 30% of the Company’s securities, respectively, with additional nomination rights upon a specified breach tied to a $3.0 million minimum cash balance and FDA marketing authorization by December 31, 2026.
Allurion Technologies, Inc. has an effective prospectus covering the resale of up to 65,211,325 shares of common stock, and this supplement adds details from a new current report. The company agreed to a $5 million private placement of 2,994,012 common shares and accompanying warrants at $1.67 per share and warrant, with the warrants exercisable after stockholder approval of the underlying shares, which the company must seek by January 31, 2026.
Allurion also signed an exchange agreement with RTW to swap all amounts outstanding under certain convertible notes and two revenue interest financing agreements for newly created Series B convertible preferred stock with a stated value of
Allurion Technologies (ALUR) announced two financing moves. The company agreed to a private placement of 2,994,012 common shares with accompanying warrants to purchase up to 2,994,012 shares, for an aggregate purchase price of about $5 million at $1.67 per share and warrant. The warrants are exercisable after stockholder approval at an exercise price of $1.67 and expire five years after approval, with a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election). A resale registration is targeted to be filed by January 10, 2026; Roth Capital Partners will receive a 7% cash fee on gross proceeds and up to $100,000 in expenses.
Separately, Allurion agreed with RTW to exchange its outstanding notes and obligations under two revenue interest financing agreements for newly created Series B convertible preferred stock, subject to stockholder approval no later than January 31, 2026. Each preferred share has a $1,000 stated value, accrues 8.25% dividends, and is convertible at $3.37 per share (subject to adjustment) with a 9.9% beneficial ownership limit. In a related step, on November 4–5, 2025, RTW converted approximately $5 million of notes at the floor conversion price of $3.35, receiving 1,492,539 common shares.